Hai-Ning Chen1, Zhu Wang2,3, Xiao Li4, Zong-Guang Zhou5. 1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China. 2. Institution of Interventional Radiology, West China Hospital, Sichuan University, Chengdu, China. 3. Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China. 4. Institution of Interventional Radiology, West China Hospital, Sichuan University, Chengdu, China. simonlixiao@126.com. 5. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China. zhou767@hotmail.com.
Abstract
BACKGROUND: The effect of Helicobacter pylori (H. pylori) eradication on gastric cancer (GC) prevention is controversial. Intestinal metaplasia (IM) seems to be a "point of no return" in the precancerous cascade. We performed a meta-analysis of randomized controlled trials (RCTs) to illustrate this issue. MATERIALS AND METHODS: The MEDLINE, EMBASE, Cochrane Library were searched for relevant RCTs that were published in any language up to March 2014. By dividing participants into subgroups based on their baseline diagnoses as group <IM (normal, non-atrophic gastritis, atrophic gastritis) and group ≥ IM(intestinal metaplasia, dysplasia), the relative risk (RR) of GC in each study compared treatment group with control group were pooled using Mantel-Haenszel fixed-effect model and publication bias analyses were performed. RESULTS: Ten studies from eight RCTs were included in this analysis, for a total of 7,955 participants. H. pylori treatment compared with control significantly reduced the risk of GC, with a pooled RR of 0.64 (95% CI, 0.48-0.85). Subgroup analysis for patients with non-atrophic gastritis, atrophic gastritis (<IM) yielded a similar results (RR = 0.25, 95% CI, 0.08-0.81). But this difference was not observed in patients with intestinal metaplasia, dysplasia (≥ IM) (RR = 0.88; 95% CI, 0.59-1.31). CONCLUSIONS: Our results suggested that patients with Intestinal metaplasia or dysplasia could not benefit from the H. pylori treatment on the risk of GC.
BACKGROUND: The effect of Helicobacter pylori (H. pylori) eradication on gastric cancer (GC) prevention is controversial. Intestinal metaplasia (IM) seems to be a "point of no return" in the precancerous cascade. We performed a meta-analysis of randomized controlled trials (RCTs) to illustrate this issue. MATERIALS AND METHODS: The MEDLINE, EMBASE, Cochrane Library were searched for relevant RCTs that were published in any language up to March 2014. By dividing participants into subgroups based on their baseline diagnoses as group <IM (normal, non-atrophic gastritis, atrophic gastritis) and group ≥ IM(intestinal metaplasia, dysplasia), the relative risk (RR) of GC in each study compared treatment group with control group were pooled using Mantel-Haenszel fixed-effect model and publication bias analyses were performed. RESULTS: Ten studies from eight RCTs were included in this analysis, for a total of 7,955 participants. H. pylori treatment compared with control significantly reduced the risk of GC, with a pooled RR of 0.64 (95% CI, 0.48-0.85). Subgroup analysis for patients with non-atrophic gastritis, atrophic gastritis (<IM) yielded a similar results (RR = 0.25, 95% CI, 0.08-0.81). But this difference was not observed in patients with intestinal metaplasia, dysplasia (≥ IM) (RR = 0.88; 95% CI, 0.59-1.31). CONCLUSIONS: Our results suggested that patients with Intestinal metaplasia or dysplasia could not benefit from the H. pylori treatment on the risk of GC.
Authors: Peter Malfertheiner; Francis Megraud; Colm A O'Morain; John Atherton; Anthony T R Axon; Franco Bazzoli; Gian Franco Gensini; Javier P Gisbert; David Y Graham; Theodore Rokkas; Emad M El-Omar; Ernst J Kuipers Journal: Gut Date: 2012-05 Impact factor: 23.059
Authors: H Miwa; S Hirai; A Nagahara; T Murai; T Nishira; S Kikuchi; Y Takei; S Watanabe; N Sato Journal: Aliment Pharmacol Ther Date: 2000-03 Impact factor: 8.171
Authors: T Kamada; K Haruma; J Hata; H Kusunoki; A Sasaki; M Ito; S Tanaka; M Yoshihara Journal: Aliment Pharmacol Ther Date: 2003-07-15 Impact factor: 8.171
Authors: Benjamin Chun-Yu Wong; Shiu Kum Lam; Wai Man Wong; Jian Shun Chen; Ting Ting Zheng; Rui E Feng; Kam Chuen Lai; Wayne Hsing Cheng Hu; Siu Tsan Yuen; Suet Yi Leung; Daniel Yee Tak Fong; Joanna Ho; Chi Kong Ching; Jun Shi Chen Journal: JAMA Date: 2004-01-14 Impact factor: 56.272
Authors: Helena T J I De Leest; Kirsti S Steen; Elisabeth Bloemena; Willem F Lems; Ernst J Kuipers; Mart A F J Van de Laar; J W J Bijlsma; Matthijs Janssen; Harry H M L Houben; Piet J Kostense; Maarten Boers; Ben A C Dijkmans Journal: J Clin Gastroenterol Date: 2009-02 Impact factor: 3.062
Authors: E M Witteman; M Mravunac; M J Becx; W P Hopman; J S Verschoor; G N Tytgat; R W de Koning Journal: J Clin Pathol Date: 1995-03 Impact factor: 3.411
Authors: Matthew Banks; David Graham; Marnix Jansen; Takuji Gotoda; Sergio Coda; Massimiliano di Pietro; Noriya Uedo; Pradeep Bhandari; D Mark Pritchard; Ernst J Kuipers; Manuel Rodriguez-Justo; Marco R Novelli; Krish Ragunath; Neil Shepherd; Mario Dinis-Ribeiro Journal: Gut Date: 2019-07-05 Impact factor: 23.059